Fruzaqla given in combination with sintilimab slowed progression in the second line for those with locally advanced or metastatic renal cell carcinoma.
Hutchmed (HCM) stock rises despite a 2024 revenue miss as a cancer drug combo it developed with Innovent Biologics (IVBYI) ...
Clinical Trials Arena on MSN10h
Innovent & HUTCHMED seek approval of kidney cancer combo after Phase II/III trialChinese-based Innovent Biologics and HUTCHMED are eyeing approval for their cancer combination after a joint Phase II/III ...
An expert discusses how medical professionals are increasingly utilizing circulating tumor DNA (ctDNA) and tissue PD-L1 to ...
An expert discusses how the availability of subcutaneous (SC) immune checkpoint inhibitors (ICI) for bladder cancer impacts ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback